<?xml version="1.0" encoding="UTF-8"?>
<ref id="B206-ijms-21-05559">
 <label>206.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Nie</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Wang</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Liu</surname>
    <given-names>Y.</given-names>
   </name>
   <name>
    <surname>Yang</surname>
    <given-names>Q.</given-names>
   </name>
   <name>
    <surname>Mei</surname>
    <given-names>Q.</given-names>
   </name>
   <name>
    <surname>Dong</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Li</surname>
    <given-names>X.</given-names>
   </name>
   <name>
    <surname>Liu</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Ku</surname>
    <given-names>W.</given-names>
   </name>
   <name>
    <surname>Zhang</surname>
    <given-names>Y.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Addition of Low-Dose Decitabine to Antiâ€“PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma</article-title>
  <source>J. Clin. Oncol.</source>
  <year>2019</year>
  <volume>37</volume>
  <fpage>1479</fpage>
  <lpage>1489</lpage>
  <pub-id pub-id-type="doi">10.1200/JCO.18.02151</pub-id>
  <?supplied-pmid 31039052?>
  <pub-id pub-id-type="pmid">31039052</pub-id>
 </element-citation>
</ref>
